Vera Therapeutics (VERA) CEO trades 18,500 shares via 10b5-1 option exercise
Rhea-AI Filing Summary
Vera Therapeutics, Inc. President and CEO Marshall Fordyce reported option exercises and share sales in Class A Common Stock. On June 23, 2026, he exercised options for 18,500 shares at an exercise price of $2.8968 per share, increasing directly held common stock by the same amount. The related option position showed 572,051 derivative shares beneficially owned after the exercise. On the same date, he sold 18,412 shares at a weighted-average price of $37.9311 and an additional 88 shares at $38.43 per share. The sales were made pursuant to a written trading plan adopted on January 9, 2026 that meets Rule 10b5-1(c) requirements.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 18,500 shares ($648K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Fordyce Marshall
Role
PRESIDENT AND CEO
Sold
18,500 shs ($702K)
Approx. gross sale proceeds
$702K
Approx. exercise cost
$54K
Approx. pre-tax spread
$648K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F4 | 18,500 | $0.00 | $0.00 |
| Exercise | Class A Common Stock F1 | 18,500 | $2.8968 | $54K |
| Sale | Class A Common Stock F2, F3, F1 | 18,412 | $37.9311 | $698K |
| Sale | Class A Common Stock F2, F1 | 88 | $38.43 | $3K |
Holdings After Transaction:
Stock Option (Right to Buy) — 572,051 shares (Direct);
Class A Common Stock — 235,244 shares (Direct)
Footnotes (4)
- F1. This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)".
- F2. The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.315, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F4. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.
Key Figures
Options exercised: 18,500 shares
Exercise price: $2.8968 per share
Shares sold (main block): 18,412 shares at $37.9311
+3 more
6 metrics
Options exercised
18,500 shares
Stock options exercised for Class A Common Stock on June 23, 2026
Exercise price
$2.8968 per share
Exercise price for the 18,500 stock options converted to Class A Common Stock
Shares sold (main block)
18,412 shares at $37.9311
Weighted-average price sale on June 23, 2026 in multiple trades
Additional shares sold
88 shares at $38.43
Separate sale of Class A Common Stock on June 23, 2026
Derivative holdings after exercise
572,051 shares
Amount of securities beneficially owned following the reported option exercise
Option expiration date
December 15, 2030
Expiration of stock option from which 18,500 shares were exercised
Key Terms
Rule 10b5-1(c), weighted-average price, Stock Option (Right to Buy), Class A Common Stock
4 terms
Rule 10b5-1(c) regulatory
"a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted-average price financial
"The price reported is a weighted-average price. These shares were sold in multiple transactions"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Vera Therapeutics (VERA) CEO Marshall Fordyce do in this Form 4/A?
Marshall Fordyce exercised options for 18,500 shares of Class A Common Stock and sold 18,500 shares in total on June 23, 2026, reflecting both acquisition through exercise and same-day market sales.
How many Vera Therapeutics (VERA) options did the CEO exercise and at what price?
He exercised 18,500 stock options for Class A Common Stock at an exercise price of $2.8968 per share. These options were originally scheduled to vest over time, with vesting beginning in December 2021.
Were Marshall Fordyce’s Vera Therapeutics (VERA) stock sales under a 10b5-1 plan?
Yes. The filing states the sales were made under a written plan adopted on January 9, 2026 that meets the requirements of Rule 10b5-1(c), indicating a pre-arranged trading program.
What is Marshall Fordyce’s remaining derivative position in Vera Therapeutics (VERA) after this transaction?
Following the reported option exercise, he beneficially owned 572,051 derivative shares tied to stock options. These options have an expiration date of December 15, 2030, according to the filing’s transaction detail.
What does the amended Vera Therapeutics (VERA) Form 4/A correct?
The amendment states it is filed to reflect the option exercise on June 23, 2026 and to correct amounts previously reported in the column for securities beneficially owned after the transactions.